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Abstract:  14 
Epilepsy is considered the most frequent severe neurological condition but most patients treated with medication become 15 
seizure free. The management of treatment however is highly empirical, mainly relying on observation. A closed-loop 16 
therapy for epilepsy would be very valuable for more efficient treatment regimens. Here we discuss monitoring treatment 17 
(therapeutic drug monitoring) and the potential developments in this field, as well as providing a review of potential 18 
biomarkers that could be used to monitor the disease activity. . Finally, we consider the pharmacogenetic input in epilepsy 19 
treatment.  20 
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 23 
1. INTRODUCTION 24 
 Epilepsy is one of the most prevalent 25 
neurological diseases. It is characterised by 26 
spontaneous epileptic seizures and defined either by 27 
the occurrence of two unprovoked seizures, or one 28 
seizure associated with a biological background 29 
making the risk of recurrence very likely 1. The 30 
lifelong prevalence of the disease in the general 31 
population is one person in 26 2 and along with 32 
seizures, this condition harbours significant morbidity 33 
and premature mortality 3. The majority of people 34 
living with epilepsy (>70%) are treated with 35 
antiepileptic drugs (AEDs) over a long-term 4. AEDs 36 
can control seizures in 60-80% of patients 5, 6 and in up 37 
to 50%, control of seizures is achieved with the first 38 
AED tried, after titration to reach the minimal effective 39 
dose. However, if the first AED fails, the probability of 40 
controlling seizures decreases with each additional 41 
AED tried, until after six tested AEDs, the chances of 42 
controlling seizures with medication becomes 43 
negligible 7. Despite epilepsy treatment having evolved 44 
over a century (in terms of drugs used), the treatment 45 
basis still relies on observation to adjust or change 46 
medication 8. If an event (seizure) occurs then 47 
treatment dosage is modified or treatment switched, 48 
but otherwise   therapy continues as is. This process 49 
inevitably takes time, during which patients are 50 
exposed to seizures with all the associated risks of 51 
injury and socio-professional difficulties. The lack of 52 
reliable biomarkers that could objectively monitor the 53 
activity of the disease between or before seizures is a 54 
major limitation. Electroencephalogram (EEG), a 55 
leading tool in the diagnosis and characterisation of 56 
epilepsy provides useful prognostic values for the 57 
long-term course 9, 10, but is unable to predict the short-58 
term evolution or response to treatment. The 59 
identification of a number of proteins (such as 60 
inflammatory cytokines) whose serum levels are 61 
associated with seizures raises hope of identifying 62 
useful biomarkers. Although these proteins were 63 
mostly shown to peak after seizures, some remained 64 
steadily increased between seizures, potentially 65 
reflecting the overall disease activity. The ability to 66 
closely follow disease activity while monitoring AED 67 
levels 11 might bring a closed-loop therapy for epilepsy 68 
for the future. The use and prescription of newer 69 
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generation AEDs (lamotrigine and levetiracetam for 70 
instance) are continually increasing 12, and although 71 
new treatments show less pharmacokinetic variability 72 
than older generation AEDs, their bioavailability 73 
significantly changes with co-mediation or 74 
physiological modifications, such as pregnancy 13-15. 75 
Monitoring drug levels of newer generation AEDs may 76 
therefore also be useful. In a closed-loop therapy, 77 
adjustment of the treatment would be directly 78 
correlated with disease activity allowing more efficient 79 
control (mostly in terms of speed) of the disease. 80 
Another input in the closed- loop could come from 81 
pharmacogenetics data providing the possibly to 82 
predict, in the future, response to treatment as well as 83 
risk of adverse events with view to personalized 84 
medication. Currently, the most valuable addition to 85 
treatment tailoring that pharmacogenetics provides is 86 
prediction of adverse events. 16, 17.  87 
Overall the possibility of closed-loop therapy in 88 
epilepsy (Figure 1) allowing treatment adjustment 89 
according to biological parameters would not replace 90 
individual discussions between the patient and his/her 91 
physician, but rather contribute a helpful tool for 92 
treatment decisions. We review here the limitations of 93 
current epilepsy treatment and examine available 94 
biomarkers for disease tracking, treatment exposure, as 95 
well as genetic predictors that could be useful for 96 
future management of epilepsy patients. 97 
2. Why monitor disease activity? 98 
The decrease in seizure frequency as a measure of 99 
treatment efficacy is based on the patient’s report. 100 
Personal reporting of seizure in the doctor’s surgery 101 
could be biased by particular circumstances such as 102 
needing to hold on to a driver’s licence. Beyond 103 
conscious misreport, recognition of seizures can also 104 
be an issue. Indeed, Evidence from EEG monitoring 105 
shows that seizures are commonly underreported as 106 
patients fail to report 55% of all recorded seizures in 107 
EEG monitoring units. Nocturnal seizures are the most 108 
underreported (85%) 18. The study concluded that 109 
failure to report some seizures was due to postictal 110 
seizure confusion. Further results from another study 111 
in an EEG monitoring unit showed similar findings 112 
with only 44.5% of complex partial and secondarily 113 
generalized tonic-clonic seizures recognized by 114 
epilepsy patients 19.  115 
Assessing the outcome or the effect of a therapeutic 116 
intervention based on a relative decrease of the seizure 117 
frequency is also flawed by other features. The 118 
duration of observation to sense a significant change in 119 
seizure frequency is influenced by the stochastic 120 
fluctuations in seizure frequency and misinterpretation 121 
due to the phenomenon of regression to the median is 122 
common place. This phenomenon is well described by 123 
Spilker and Segreti 20 following their observation of 124 
“oscillations” of seizure frequency in a controlled 125 
clinical trial of cinromide versus placebo in patients 126 
with focal epilepsy 21. They suggested several factors 127 
that could cause different rhythms of seizure 128 
frequency, for instance, hormonal cycles of menstrual 129 
periods, circadian rhythms, as well as phases of the 130 
moon. The authors performed three analyses of 131 
changes in seizure frequency from six previous studies 132 
(in placebo arms) and confirmed presence of 133 
regression of seizure frequency towards the median, 134 
observed in all types of epilepsy. Overall, patients who 135 
had high seizure frequencies tended to experience a 136 
reduction in frequency, while patients with low seizure 137 
frequencies rather experienced an increase. This study 138 
showed that epilepsy patients manifest changes in 139 
seizure frequency irrespective of treatment. This 140 
finding becomes more relevant in the assessment of 141 
response to a new treatment as patients are often 142 
started on increased dosage or new medication when 143 
they experience an increase in seizure frequency, 144 
making it very likely that whatever medication is used, 145 
a decrease in seizure frequency will be observed as 146 
part of the regression to the median. This regression 147 
can appear as a honeymoon, as the medication is 148 
considered initially efficacious but then the effect fades 149 
away 22.  Consequently, response to a medication 150 
cannot be fully assessed using common standards used 151 
in regulatory studies, such as 50% seizure frequency 152 
reduction over 3 months23.  153 
The International League Against Epilepsy (ILAE)  154 
proposed the “rule of three”24 to define seizure 155 
freedom as ‘without seizure for three times the pre-156 
intervention inter-seizure duration or at least one year’ 157 
25. The rule of three was recently reassessed 26 and in 158 
some cases of refractory epilepsy (the probability of 159 
success of an intervention being 5%), ‘six times the 160 
pre-intervention inter-seizure duration’ would be more 161 
adequate, supporting the ILAE’s definition of the 162 
shortest period to assess the response to the treatment 163 
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as 1 year in all cases. Although it appears robust, the 164 
ILAE definition of drug response, leads to long periods 165 
of observation so that predicting treatment response in 166 
the short-term is not possible. 167 
The poor understanding of the natural course of 168 
epilepsy also makes it difficult to assess response to 169 
treatment. Some types of epilepsy have spontaneous 170 
transitory remission periods, as in genetic generalized 171 
epilepsy after adolescence, or definitive remission in 172 
childhood epilepsies, like childhood absence epilepsy 173 
or myoclonic epilepsy in infancy that enter remission 174 
during adolescence 27, 28. In refractory epilepsy, some 175 
patients may experience a pattern of intermittent 176 
remission alternating with relapses 29. Some of these 177 
periods of remission are likely to be spontaneous and 178 
not treatment related 30. Aging also seems to increase 179 
drug responsiveness in patients with drug-resistant 180 
epilepsy 3. Altogether these data suggest that the 181 
natural course of epilepsy cannot be considered as 182 
stable and its fluctuations cannot currently be 183 
predicted. 184 
The points discussed above highlight the difficulties of 185 
predicting and monitoring the course of epilepsy and 186 
its response to medication. These difficulties renders 187 
management of people with epilepsy mostly empirical 188 
with help of a few tools. 189 
3. Current tools for follow-up of epilepsy 190 
EEG is a major tool in the assessment of epilepsy, but 191 
its usefulness in epilepsy follow-up of is arguable. 192 
Several studies did not find predictive usefulness of 193 
EEG patterns in neonates, children with West 194 
syndrome and febrile seizures 31, 32 and there is only 195 
limited data on its predictive value on the course of the 196 
disease, despite its widespread use. A study carried out 197 
in 39 patients with epilepsy investigated the 198 
relationship between serial EEG recordings and 199 
clinical outcome over 15 years follow-up, concluded 200 
that patients with epileptiform discharges on repeated 201 
EEG recordings had a worse outcome compared to 202 
whose with normal initial EEG in terms of seizure 203 
control and social outcomes 10. Absence of generalized 204 
epileptiform activity in the EEG was associated with a 205 
good prognosis in a community study 9.  206 
It is widely agreed that the hallmark of epilepsy is an 207 
imbalance between cortical excitability and inhibition 208 
33. Levels of EEG activity synchrony were found to 209 
correlate with antiepileptic drug changes, suggesting 210 
that this would reflect on the cortical excitability (34). 211 
Transcranial magnetic stimulation (TMS) similarly 212 
showed motor threshold and cortical excitability on 213 
recovery curves predicting response to medication. A 214 
decrease in cortical excitability occurred in the seizure-215 
free patients indicated by increased motor thresholds 216 
and intracortical inhibition on recovery curve analysis 217 
compared to pretreatment values 34. TMS combined 218 
with EEG was studied as a diagnostic tool in 25 219 
patients with genetic generalized epilepsy, comparing 220 
to 11 controls and was able to reliably differentiate 221 
patients with epilepsy from control subjects. 222 
Furthermore, patients with drug resistant epilepsy had 223 
higher amplitude late TMS-EEG responses compared 224 
to controls 35.  In another study TMS combined with 225 
EEG performed on 8 patients with periventricular 226 
nodular heterotopia showed an increased late cortical 227 
motor response compared to the matched controls, 228 
which was suggested to reflect the cortical 229 
hyperexcitability due to altered connectivity 36. These 230 
measurements however are very liable to influence 231 
from many other factors, such as the point in the 232 
menstrual cycle in women 33. Some authors wondered 233 
if the increased excitability found in TMS could be a 234 
biomarker of epilepsy 37, but the large inter-individual 235 
variability seems to preclude establishment of  236 
normative values 38. Variations on an intra-individual 237 
basis could however be useful to monitor cortical 238 
excitability. 239 
More recently, high frequency oscillations (HFO) in 240 
invasive intracranial EEG recordings were found to be 241 
tightly co-localised with the seizure onset zone and 242 
were suggested to be a biomarker of epilepsy 39. These 243 
signals were reported to be recordable on the scalp in a 244 
non-invasive setting (although this technique may not 245 
be flawless 40, 41), potentially opening up to widespread 246 
use 42. There is currently limited data on the evolution 247 
of high frequency oscillations over the course of 248 
epilepsy though. A recent study showed correlation 249 
between the number of ripples and the risk of 250 
developing seizures in children with rolandic spikes. 251 
The presence of more than two ripples (in a 10-minute 252 
EEG recording) related to rolandic spikes increases the 253 
risk of having seizures. More than five ripples 254 
predicted a malignant course in rolandic epilepsy 43.  255 
The same group published a retrospective study 256 
showing that patients with fast ripples in the 257 
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intraoperative corticogram had higher risk of seizure 258 
recurrence 44. 259 
Overall, the management of epilepsy subjects is 260 
currently largely a process of trial and error. It is likely 261 
to remain so in the near future at least, given the great 262 
heterogeneity of epilepsies and individual patient 263 
situations. Improved monitoring of disease activity on 264 
treatment would however make the process more 265 
efficient, determining, for instance, early in the course 266 
of a treatment if it is likely to be efficacious or not. 267 
 268 
4. Potential epilepsy biomarkers 269 
There are numerous systemic changes reported during 270 
seizures, beyond the classical increase in serum 271 
creatinine kinase45 and lactate46. 272 
Seizures have an enduring effect on multiple somatic 273 
systems, leading to the premature occurrence of 274 
somatic co-morbidities and premature mortality 275 
independent of the pre-existing health 3. This 276 
association between widespread systemic changes and 277 
seizures suggests that seizures lead to the release of 278 
circulating mediators that could be detected in 279 
biological samples such as serum. There are 280 
suggestions that at least some of these widespread 281 
changes are associated with increased inflammatory 282 
parameters 47.  283 
4a. Cytokine changes  284 
Here we discuss cytokine changes induced by seizures, 285 
however the immune system and associated 286 
inflammatory reactions also play an important role in 287 
epileptogenesis 48. We will concentrate on cytokine 288 
changes associated with established epilepsy. A 289 
comprehensive review and meta-analysis of this aspect 290 
can be found in the excellent paper of De Vries et al. 291 
49. 292 
Several studies assessed serum and cerebrospinal fluid 293 
(CSF) IL-1 levels in patients with focal and genetic 294 
generalized epilepsy in the first hours post seizure and 295 
in the interictal period compared to control subjects. 296 
Results were mostly negative, with no significant 297 
changes in the IL-1β serum concentrations in a 24h 298 
period after tonic-clonic seizures compared to control 299 
subjects 50-54. Increased interictal serum IL-1 levels 300 
were at times reported in patients with temporal lobe 301 
epilepsy compared to extra-temporal lobe epilepsy and 302 
control subjects 55.  303 
Interleukin 6 (IL-6) is a multifunctional cytokine 304 
regulating inflammatory responses. It was shown to be 305 
increased in several neurological conditions such as 306 
Alzheimer’s disease, trauma and meningitis 56. Serum 307 
and CSF IL-6 levels have been studied in epilepsy 308 
patients with recent seizures (<72h), where levels were 309 
found to be higher than in seizure-free patients and 310 
controls 55. Serum IL-6 levels were increased 311 
interictally within 24h of a seizure, particularly in 312 
patients with temporal lobe epilepsy 54, 57, 58. The levels 313 
were shown to decrease after resection of the 314 
epileptogenic lesion in these patients 59. CSF and 315 
serum IL-6 were also reported to be correlated with 316 
epilepsy severity, assessed in terms of seizure 317 
frequency (measured by seizure diaries), as well as 318 
seizure intensity, scored using the National Hospital 319 
Seizure Severity Scale (NHS3) and the Veterans 320 
Administration Seizure Frequency and Severity Rating 321 
Scale score (VA score) in 1, 218 patients with 322 
symptomatic epilepsy compared to 200 control 323 
subjects 50, 60.  324 
The IL-17A receptor (IL-17RA) is highly expressed in 325 
focal cortical dysplasia, a major cause of epilepsy 61. In 326 
one prospective study, interictal serum and CSF IL-327 
17A  levels were increased in 70 patients with focal 328 
non-lesional epilepsy compared to 68 healthy controls. 329 
Patients with somatic co-morbidities were excluded. 330 
Serum IL-17A levels were independently associated 331 
with seizure severity, evaluated by the NHS3 and the 332 
VA score)60 and seizure frequency (measured by 333 
seizure diaries) 61. IL-17A serum levels were also 334 
reported to correlate with interval to the next seizure in 335 
focal epilepsy 50  336 
Other inflammatory markers have been studied, for 337 
example Interferon λ 3 (IFN λ)  CSF and serum levels 338 
which were found to be correlated with seizure severity 339 
and interval to next seizure in temporal lobe epilepsy 340 
50.  Serum levels of interferon (IFN) γ and IL-8 were 341 
also suggested to correlate with seizure severity (NHS3 342 
scale and VA score) 50; Increased levels of C reactive 343 
protein (CRP) were also found in serum of patients 344 
with refractory temporal lobe epilepsy compared to 345 
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controls 62; this increase was more marked 3-6 hours 346 
after a generalized tonic-clonic seizure. 347 
Inflammatory mediators appear to have important 348 
potential as biomarkers for epilepsy. However, 349 
although there are consistent results showing changes 350 
in inflammatory mediators in epilepsy, none of the 351 
changes are specific to the disease and some of them 352 
may be the consequence of the underlying condition. 353 
Increased inflammatory mediators do not appear to be 354 
related to traumatic consequences of seizures as 355 
changes were demonstrated in EEG monitoring units, 356 
where trauma due to seizures is much less likely than 357 
in everyday life. Another potential pitfall in use of 358 
inflammatory mediators as part of a biomarker panel is 359 
their relatively low concentrations which may lead to 360 
difficulties in detecting them by standard proteomic 361 
techniques. 362 
1. 4b Hormonal changes  363 
Hormonal changes (mostly sexual hormones in 364 
females) are well known to interact with epilepsy. 365 
Mesio-temporal epilepsy has been shown to deregulate 366 
luteinising hormone secretion in one study 63 where 367 
secretion of luteinizing hormone was detected 368 
interictally and postictally in women with mesio-369 
temporal epilepsy during two 24-hour epochs (an 370 
interictal baseline and in the postictal period) 371 
compared to males. The authors found that seizures 372 
provoked timing irregularity in luteinizing hormone 373 
secretion, whereas chronic epilepsy was related to 374 
modifications in luteinizing hormone pulse frequency, 375 
amplitude and mass. Even though the exact mechanism 376 
of this dysregulation is not clear, it is probable that 377 
mesial temporal epilepsy alters hypothalamic 378 
functions. Epileptic discharges in the left temporal 379 
region have been associated with increased LH/FSH 380 
ratios and testosterone levels 64. This altered LH/FSH 381 
ratio and testosterone levels might conceivably be a 382 
biomarker of mesio-temporal lobe epilepsy. 383 
Fluctuations of sexual hormones in women are known 384 
to modulate cortical excitability and therefore the 385 
occurrence of seizures. Studies using TMS showed 386 
cortical excitability varies according to the phase of the 387 
menstrual period in healthy women 65, 66. Cortical 388 
hyperexcitability is increased in the luteal phase in 389 
female patients with catamenial seizures compared to 390 
control women33. 391 
A case study assessed plasma levels of prolactin, 392 
noradrenaline, vasopressin and oxytocin during and 393 
after focal secondarily generalized seizures 67. 394 
Prolactin levels were found to increase at the beginning 395 
of aura until the end of the generalized tonic- clonic 396 
seizure, this increase was correlated with the intensity 397 
and the duration of the seizure 68. Levels of 398 
noradrenaline, vasopressin and oxytocin remained 399 
stable during the aura, but increased in the generalized 400 
phase 67. 401 
Recently, hair cortisol levels were postulated as a 402 
biomarker of chronic stress in the months preceding a 403 
first seizure. Twenty two subjects with a first epileptic 404 
seizure were compared to twenty nine control subjects. 405 
Increased hair cortisol-levels were found within twenty 406 
four hours following seizure compared to the control 407 
group, possibly reflecting hyperactivity of the 408 
hypothalamic-pituitary- adrenal axis 69. A positive 409 
relationship between cortisol levels and epileptiform 410 
discharges on long-term (> 24h) EEG recordings was 411 
also reported in patients with focal epilepsy, who 412 
reported seizures related to stress 70. A recent review 413 
assessing the occurrence of seizures according to the 414 
circadian cycle, found that seizures were more frequent 415 
in the morning, possibly linked to the peak of 416 
cortisol71.  417 
 418 
Although hormonal changes are well demonstrated 419 
consequences of seizures, there is less evidence on 420 
interictal changes. Interictal hormonal changes may 421 
indeed be the consequences of AED medication-422 
induced liver induction72. Natural short term 423 
fluctuations (circadian and menstrual cycles) may 424 
render hormonal levels potentially less useful for long-425 
term course biomarkers of disease. 426 
 427 
4c. Other biological and physical changes 428 
People with epilepsy (mainly those with TLE) have 429 
been shown to have interictally decreased heart rate 430 
variability 73-75 independent of antiepileptic medication 431 
that could be related to seizure frequency 76, 77. One 432 
study assessed autonomic functions (heart rate 433 
variability) in 21 patients with juvenile myoclonic 434 
epilepsy and 21 with temporal lobe epilepsy, treated 435 
with carbamazepine, valproate or phenytoin compared 436 
to control subjects. Patients with temporal lobe 437 
epilepsy treated with carbamazepine had lower heart 438 
rate variability than controls, suggesting decreased 439 
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sympathetic tone 75. There was no significant heart rate 440 
variability difference in patients with juvenile 441 
myoclonic epilepsy compared to controls. A recent 442 
study demonstrated that patients suffering from 443 
temporal lobe epilepsy had more marked reduced heart 444 
rate variability at night than in daytime, and nocturnal 445 
heart rate variability increase did not appear. This 446 
suggested a suppression of circadian heart rate 447 
dynamics in patients with temporal lobe epilepsy 78.  448 
 449 
There is some evidence that seizures induce an 450 
elevation of troponin I, a marker of cardiac injury 79. In 451 
a small series of 11 people assessed for epilepsy 452 
surgery, no troponin I elevation was observed after 453 
mostly complex partial seizures 80.  A study of 30 454 
complicated (followed by significant systemic 455 
repercussions such as desaturation or hypotension) 456 
seizures compared to 30 uncomplicated generalized 457 
tonic-clonic seizures 81 found significantly higher 458 
troponin I values after complicated rather than 459 
uncomplicated seizures; all values were, however, 460 
within the normal range. Finally a recent large study of 461 
741 consecutive people admitted to hospital with 462 
generalized tonic-clonic seizures, 82 found an elevation 463 
of troponin I in 6.7% after seizures. None of the 6.7% 464 
had known ischemic heart disease, and troponin I 465 
elevation was asymptomatic in all cases. There was no 466 
obvious explanation for these elevations; Takotsubo 467 
cardiomyopathy was excluded by echocardiography, 468 
and serial ECGs and monitoring were unremarkable in 469 
these people.  470 
Most cardiovascular changes seem to be short-term 471 
consequences of seizures and are therefore unlikely to 472 
represent useful biomarkers for long-term disease 473 
activity. Cardiac autonomic dysfunction (heart rate 474 
variability) may be a chronic feature associated with 475 
epilepsy, but it may also be the consequence of 476 
repeated seizures rather than the underlying disease 477 
activity. 478 
 479 
Changes in microRNA (miRNA) expression were 480 
described to be associated with epilepsy. The analysis 481 
of miRNA profiles in autopsy hippocampal tissue 482 
found 165 miRNAs up-or-down-regulated in patients 483 
with temporal lobe epilepsy compared to healthy 484 
control tissue 83. Recent studies showed that miRNAs 485 
may play an important wide role in epilepsy and its 486 
treatment. Animal studies demonstrated that silencing 487 
a specific miRNA (miR-134) with antisense 488 
oligonucleotides had an anti-seizure effect, while 489 
deletion of miR-128 caused refractory epilepsy. 490 
Studies on DNA-methylation revealed epigenetic 491 
regulation of miRNA levels and synthesis 84. This was 492 
seen in patients with mesio-temporal epilepsy who had 493 
altered DNA methylation of several miRNAs (miRNA 494 
27A, miR-193a-5p and miR-876-3p), thought to 495 
contribute to neuronal development and remodeling 85. 496 
MiRNAs could be potential epilepsy biomarkers due to 497 
their tissue-specific expression 86, as well as their 498 
stability and ease of detection in most biological 499 
materials, such as serum.  At this stage further work is 500 
needed to understand the relationship between 501 
potential alterations in miRNA expression and disease 502 
activity in terms of seizure frequency. 503 
 504 
4d. Future of epilepsy biomarkers 505 
 506 
The systemic changes induced by seizures make it 507 
likely at some point to monitor disease activity. Table 508 
1 summarizes the potential epilepsy biomarkers and 509 
their relationship with seizures. Changes demonstrated 510 
as present interictally are obviously more relevant than 511 
modifications only found post-ictally. None of the 512 
changes listed above are specific to the disease; the 513 
future lies probably in a combination of markers that 514 
together reach sufficient specificity and sensitivity. 515 
The usefulness of such combined biomarkers will need 516 
to correlate with statistically robust clinical outcome, 517 
such as seizure freedom defined by the rule of 3 26. 518 
One question remaining is will these markers reflect on 519 
past occurrence of seizures or monitor the propensity 520 
of new seizures to come, which would be more useful. 521 
Some of the changes discussed above (maily elevated 522 
cytokines) are present even between seizures, which 523 
raises the hope of monitoring the underlying disease 524 
activity that triggers seizures. Current evidence is 525 
however insufficient to ascertain that interictal markers 526 
predict the occurrence of future seizures. Studies 527 
addressing the effects of medication on these markers 528 
are scarce (33-34-35).  529 
 530 
5. Why monitor drug exposition? 531 
 532 
Therapeutic drug monitoring (TDM) comes from the 533 
observation that the effects of some drugs correlate 534 
better to the circulating concentration than to the 535 
administered dose. TDM encompasses both drug 536 
quantification in a sample and pharmacological 537 
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interpretation with dosage adjustment if needed. Drugs 538 
in which monitoring is particularly valuable are those 539 
that display large inter-individual and low intra-540 
individual pharmacokinetic (PK) variability, as well as 541 
good correlation between blood concentrations and the 542 
clinical response/side effects 87. Some AEDs (both 543 
older and newer generation) show significant inter-544 
individual PK variability, due to interactions with or 545 
polymorphisms in hepatic cytochrome or 546 
glucuronidase substrates (phenytoin, valproate, 547 
lamotrigine, lacosamide, zonisamide) 87. Phenytoin 548 
may present nonlinear pharmacokinetics (unpredictable 549 
loss of correlation between dose and attained blood 550 
levels) at usual doses due to saturation of its 551 
elimination pathways 88. TDM can provide a useful 552 
tool to adjust the dose of medications in relation to 553 
clinical response. However, some newer generation 554 
AEDs have lower inter-individual variability because 555 
of unaltered renal excretion (gabapentin, pregabalin 556 
and levetiracetam), for which the TDM usefulness is 557 
less likely.  558 
 559 
5a. Therapeutic drug monitoring of older 560 
generation AEDs 561 
 562 
TDM of older generation AEDs is more studied than 563 
that of newer generation AEDs and is widely 564 
considered validated.   565 
 566 
In 1960, Buchthal et al. established a positive 567 
correlation between the clinical effect of phenytoin 568 
(PHT) and its serum levels in a small group of 569 
inpatients with epilepsy (12), suggesting phenytoin 570 
serum level ranges between 10-20 µg/ml 89. For these 571 
inpatients, plasma PHT level higher or equal to 10 572 
µg/mL, was associated with clinical improvement over 573 
the course of 3 to 4 weeks. Later, a three-year 574 
prospective study in outpatients (n=32) with 575 
generalized epilepsy treated with PHT showed that a 576 
phenytoin range of 10 and 20 µg/ml was the most 577 
appropriate for seizure control and  avoiding adverse 578 
events 90. The influence of plasma levels of phenytoin, 579 
carbamazepine and phenobarbital were evaluated in 78 580 
patients according to their seizure type. Mean plasma 581 
levels of AEDS were higher for controlling focal than 582 
generalized tonico-clonic seizures 91.  583 
 584 
However, a randomized clinical trial including 127 585 
patients with epilepsy concerning carbamazepine, 586 
ethosuximide, phenobarbital, primidone, or valproate 587 
failed to demonstrate that serum concentration within a 588 
therapeutic range contributed to decreased frequency 589 
of seizures. Patients were randomized into a group 590 
where drug blood levels were communicated to the 591 
treating neurologist and the dose was adjusted to reach 592 
the reference range, or into a group where blood levels 593 
were not reported to the neurologist and the dose was 594 
adjusted based on the clinical response. Results were 595 
negative, showing that routine AED TDM and 596 
adjustment of dosage to achieve therapeutic levels did 597 
not improve the treatment of patients with epilepsy 92. 598 
Another multicenter randomized controlled trial also 599 
failed to demonstrate the benefit of routine TDM of 600 
older generation AEDs 93. Despite the conclusions of 601 
these two randomized clinical trials, routine TDM 602 
continues to be used following other nonrandomized 603 
studies that showed that TDM is useful in AED 604 
treatment in some situations 94. 605 
 606 
5b. Therapeutic monitoring of newer generation 607 
AEDs 608 
 609 
The use of a newer generation AEDs is increasingly 610 
replacing the older generation AEDs 95, 96. Although 611 
newer generation AEDs have a better therapeutic index 612 
due to their better tolerance, some (lamotrigine, 613 
topiramate, tiagabine, zonisamide, and felbamate) may 614 
be good candidates for TDM 11. These particular drugs 615 
have large inter- and intra-individual pharmacokinetic 616 
variability and their metabolism is influenced by age, 617 
pregnancy, associated disease and some concomitant 618 
medication 97. There are suggestions that the effects of 619 
newer generation AEDs are correlated to their serum 620 
levels 94, 98.  TDM of lamotrigine during pregnancy is 621 
widely recommended because of the significant drop in 622 
concentrations over the course of the pregnancy 99.   623 
Current practice guidelines for TDM 100 now 624 
recommend its  use in : dose optimization of the first 625 
prescribed AED to reach a target concentration, 626 
increased seizure frequency, suspected toxicity due to 627 
accumulation, pregnancy, suspected poor compliance, 628 
risk of interactions, cases of disturbed bioavailability 629 
of the AED and whenever there is an unexpected 630 
change in clinical response. 631 
 632 
5c. Future of TDM in epilepsy 633 
 634 
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Despite current limited evidence of its usefulness 635 
(randomized trials are ongoing for newer generation 636 
AEDs), TDM will remain an important tool in the 637 
treatment of subjects with epilepsy. Several new 638 
developments however should improve its value. 639 
 640 
We need to define a better correlation between drug 641 
levels and clinical effects using more robust outcomes, 642 
such as remission. Stable patients in remission (as 643 
defined by the ILAE) not uncommonly have drug 644 
levels below the reference range, suggesting a ceiling 645 
effect, above which no remission patient is found 101, 646 
102. Such observations could prove to be useful for 647 
medication titration. 648 
The widespread use of ultra-performance liquid 649 
chromatography coupled with tandem mass 650 
spectrometry will improve reliability 103 of the 651 
measures and the use of saliva samples will make 652 
samples more readily available104.  653 
Computer applications should soon be ready for use to 654 
facilitate AED prescription. They would use 655 
population pharmacokinetic models 105, 106, describing 656 
the time course of drug exposure for a patient 657 
according to factors considered to contribute to 658 
variability (weight or other medication for example). 659 
Models are then combined with drug levels to calculate 660 
the most probable pharmacokinetic parameters for the 661 
patient (Bayesian approach) and thereby propose, if 662 
necessary, more suitable dosages.   663 
Although there is currently little evidence on the 664 
tangible benefit of TDM in epilepsy, it remains an 665 
invaluable tool to assess and make normalized drug 666 
exposures of individual patients and as such is likely to 667 
be an important part of closed-loop therapy. 668 
 669 
6. Another input to the loop: pharmacogenetics 670 
 671 
Pharmacogenetics could potentially provide precious 672 
data on the dosing, response and tolerance of AEDs. 673 
However, for now this field has lots of non-replicated 674 
studies. A recent paper reviewed the evidence level of 675 
findings 107. Genetic variation can influence the effects 676 
of AEDs through pharmacokinetic and 677 
pharmacodynamic changes, as well as through other 678 
mechanisms involved in overall drug resistance 107 679 
 680 
6a. Genetic biomarkers for pharmacological effects: 681 
pharmacodynamic aspects 682 
 683 
There are relatively few demonstrated effects of 684 
genetic variations on drug targets. Functional 685 
polymorphisms (IVS5-91 G>A) in the SCN1A (sodium 686 
voltage-gated channel) gene were shown to be 687 
associated with varying prescribed doses of phenytoin 688 
and carbamazepine spontaneously used in clinical 689 
practice 108.  Other polymorphisms of SCN1A 690 
(rs3812718) were also shown to modify the effect of 691 
carbamazepine on the cortical silent period (probably 692 
by GABA modulation) in TMS studies 109.  693 
 694 
6b. “Pharmacological correction” of genetic defects 695 
 696 
The knowledge of a specific genetic etiology might  697 
help determine the most adequate treatment. This 698 
remains an exceptional situation at present in everyday 699 
clinical practice. A well-known example is the glucose 700 
type I transporter (GLUT-1) deficiency, a genetic 701 
metabolic encephalopathy caused by a mutation in the 702 
SLC2A1 gene, encoding GLUT-1 that provokes altered 703 
transport of glucose across the blood-brain barrier. The 704 
most effective treatment is a ketogenic diet in this case. 705 
Another example is mutations in the voltage-gated 706 
sodium channel alpha 1 subunit gene (SCN1A) are 707 
associated with Dravet syndrome and epilepsy with 708 
febrile seizures plus (GEFS+). The treatment of this 709 
syndrome is less evident; the combination of 710 
stiripentol, valproate and clobazam and avoidance of 711 
sodium channel blocking AEDs are deemed to be the 712 
most efficient, although formal evidence is lacking 107. 713 
Recently, cannabinoids were also suggested to be 714 
efficacious in Dravet Syndrome 110. There are also 715 
suggestions that antiNMDA drugs like memantine 716 
could be used in children with an early onset epileptic 717 
encephalopathy due to GRIN2A mutations 111. 718 
 719 
6c. Genetic biomarkers for pharmacological effect: 720 
pharmacokinetic aspects 721 
 722 
There is much more data on the genetic variations of 723 
AED metabolism (such as in P450 cytochromes 724 
genes), affecting their pharmacokinetic properties. For 725 
instance, carrying CYP2C9 alleles with reduced 726 
activity of rs1057910 (CYP2C9*3) compared to 727 
individuals homozygous for the wild-type alleles 728 
causes a high risk of toxicity upon exposure to 729 
phenytoin 112. Although detection of these variants can 730 
help to anticipate the bioavailability of medication, 731 
they are rarely used in practice as the more readily 732 
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available serum levels provide data on the overall 733 
metabolism of the medication including drug 734 
interactions. 735 
 736 
6d. Genetic biomarkers predicting the efficacy of 737 
AEDs 738 
 739 
Genetic variations predicting pharmacoresistance have 740 
been investigated in several studies that mainly 741 
focused on multidrug transporters that expel AEDs 742 
from the CNS, but they did not reach consistent results. 743 
The drug transporters ABCC1, ABCC2 and ABCC5 744 
have been shown to be overexpressed in brain capillary 745 
endothelial cells and astroglia of patients with 746 
refractory epilepsy 113, 114. Some studies suggested an 747 
increased risk of drug resistance in patients with the c.-748 
24C>T ABCC2 polymorphisms compared to controls, 749 
which other studies failed to confirm 115. miRNAs 750 
were also recently studied for drug resistance and  751 
several miRNAs (miR-194-5p,-301a-3p, -30b-5p, -752 
342-5p and -4446-3p) were found to be increased in 753 
patients with refractory epilepsy compared to drug 754 
responsive patients. MiR-3012-3p was the most closely 755 
associated with drug-resistance, with 80.5% sensitivity 756 
and 81.2% specificity 116.  757 
 758 
6e. Genetic prediction of adverse events 759 
 760 
Prediction of adverse events is the area where 761 
pharmacogenetics contributes most to treatment of 762 
epilepsy. There is indeed strong evidence in Asian 763 
populations of an association between the HLA-764 
B*1502 allele and severe rashes, such as Stevens-765 
Johnson syndrome, provoked by treatment with CBZ 766 
17, 117. The HLA-A*3101 allele has also been shown to 767 
be associated with CBZ induced hypersensitivity 768 
reactions, from maculopapular exanthema to severe 769 
blistering reactions amongst patients of European 770 
ancestry and in the Japanese population 118, 119. While 771 
these tests are clearly useful, the lengthy delay in 772 
obtaining results renders it easier for the time being to 773 
use medications that do not require this testing as 774 
shown in Asian populations120.  775 
 776 
7. Conclusion 777 
Although hypothetical at this point, a closed-loop 778 
therapy for epilepsy has potential to improve the state 779 
of treatment which currently mostly relies upon trial 780 
and error. Two major points are hampering its 781 
development: lack of reliable experience with epilepsy 782 
biomarkers and limited correlation with medication 783 
levels and clinical effects. A set of biomarkers would 784 
probably need to be identified using modern systematic 785 
methods (“omics”) such as proteomics and 786 
metabolomics, in cross-sectional studies comparing 787 
people with controlled vs. uncontrolled epilepsy with 788 
subsequent validation in prospective studies. Similarly, 789 
AED serum levels would need to be related to more 790 
robust clinical outcomes such as remission, before 791 
being tested prospectively.  792 
The road for closed-loop therapy is therefore still long 793 
and probably paved with methodological issues, such 794 
as difficulties of validating the correlation of potential 795 
biomarkers with a robust clinical outcome in the first 796 
place. 797 
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